OCA

FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
BioPharma Dive
FDA
NASH
OCA
obeticholic acid
Intercept Pharma
Flag link:
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
Flag link:
By summer solstice, we'll know the fate of Intercept's NASH drug
By summer solstice, we'll know the fate of Intercept's NASH drug
Endpoints
Intercept Pharmaceuticals
FDA
NASH
obeticholic acid
OCA
Flag link:
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Endpoints
Intercept Pharma
OCA
obeticholic acid
FDA
NASH
Flag link:
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
Bloomberg
liver disease
NASH
Intercept Pharmaceuticals
OCA
obeticholic acid
Flag link:
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
BioSpace
NASH
Intercept Pharmaceuticals
obeticholic acid
OCA
clinical trials
Flag link:
Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
CP Wire
INTERCEPT
primary biliary cholangitis
obeticholic acid
OCA
Flag link:
Intercept cuts targets for pivotal NASH study
Intercept cuts targets for pivotal NASH study
BioPharma Dive
Intercept Pharma
NASH
clinical trials
OCA
obeticholic acid
Flag link:
FDA advisory panel supports quick approval for Intercept's drug OCA for liver disease
FDA advisory panel supports quick approval for Intercept's drug OCA for liver disease
Fierce Biotech
FDA
advisory panels
Intercept Pharma
OCA
primary biliary cirrhosis
Flag link:
3 Upcoming FDA Decisions We're Most Excited About
3 Upcoming FDA Decisions We're Most Excited About
Motley Fool
FDA
Acadia
Intercept Pharma
Clovis Oncology
Nuplazid
OCA
rociletinib
Flag link:
Intercept's much-hyped NASH drug misses the mark in Phase II
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA
Flag link:
Will This Drug Beat Gilead to Market in NASH?
Will This Drug Beat Gilead to Market in NASH?
Investopedia
Gilead Sciences
NASH
OCA
Intercept Pharma
Flag link:
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
24/7 Wall St
Amgen
evolocumab
Biogen Idec
BIIB037
OCA
obeticholic acid
Intercept Pharmaceuticals
Flag link:
Intercept Liver Drug Needs Safety Review, Researchers Say
Intercept Liver Drug Needs Safety Review, Researchers Say
Bloomberg
Intercept Pharma
OCA
Flag link:
Two drug makers diverge in Wall Street woods, and see huge moves
Two drug makers diverge in Wall Street woods, and see huge moves
Marketwatch
Intercept Pharma
OCA
Dendreon
Flag link:
Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data
Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data
TheStreet.com
Intercept Pharma
OCA
nonalcoholic steatohepatitis
Flag link:
Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS
Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS
Motley Fool
Vivus
Intercept Pharmaceuticals
M&A
Aspen Investments
OCA
Flag link:
Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show
Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show
TheStreet.com
Intercept Pharma
liver disease
OCA
obeticholic acid
Flag link:
Companies Betting on the Next 10 Blockbuster Drugs
Companies Betting on the Next 10 Blockbuster Drugs
24/7WallStreet
Juxtapid
Otezla
Aegerion
Celgene
GW Pharma
Sativex
Intercept Pharma
OCA
Ironwood Pharmaceuticals
Linzess
Lpath
iSONEP
MannKind
Afrezza
Xtandi
H.P. Acthar Gel
Questcor Pharmaceuticals
eteplirsen
Sarepta Therapeutics
Flag link:
Intercept Pharma rises as analyst raises her price and sales estimates for its liver drug OCA
Intercept Pharma rises as analyst raises her price and sales estimates for its liver drug OCA
Yahoo/AP
OCA
liver disease
Intercept Pharma
Flag link:

Pages